Work

Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities

Year: 2020

Type: article

Abstract: (Cell Reports 14, 979–990; February 9, 2016) In the originally published version of this article, there was an inadvertent duplication of the single agent controls in Figure 1E. A corrected version of the figure panel is provided here. The authors regret this error. Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique VulnerabilitiesFranco et al.Cell ReportsJanuary 21, 2016In BriefCDK4/6 inhibitors are potent inhibitors of cell cycle that are employed clinically. Franco et al. report that the inhibition of CDK4/6 in pancreatic cancer models reprograms metabolism through a pathway involving the RB tumor suppressor and MTOR activation. These findings demonstrate specific metabolic adaptations to this class of therapeutic agents and delineate vulnerabilities for future therapeutic intervention. Full-Text PDF Open Access

Source: Cell Reports

DOI: 10.1016/j.celrep.2020.107793

Authors: Jorge Franco, Uthra Balaji, Elizaveta Freinkman, Agnieszka K. Witkiewicz, Erik S. Knudsen

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $5,200

Funder: National Cancer Institute